久久久久久久97_A级毛片内射免费视频_免费精品99久久国产综合精品_国产精品无码AⅤ精品影院,少妇精品久久久一区二区三区_2021无码国产在线视频_国产区网站桃色在线观看_久久亚洲精品无码aⅴ大香,国产无套无码AⅤ在线观看|亚洲免费人成视频在线观看|亚洲av无码精品网站|热久久中文字幕人妻

供貨周期	現(xiàn)貨	規(guī)格	T-25 Flask
貨號	CBP73198	應(yīng)用領(lǐng)域	生物產(chǎn)業(yè)
主要用途	僅限科研使用

CBP73198
I. Introduction
Cell Line Name：	KIF5B(E15)-RET(E12) [V804L]/BaF3
Host Cell:	Ba/F3
Stability:	16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application:	Anti-proliferation assay and PD assay
Freeze Medium:	90% FBS+10% DMSO
Complete Culture Medium:	RPMI-1640+10%FBS
Mycoplasma Status:	Negative

II.Background
Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.

III. Representative Data
1. WB of KIF5B-RET [V804L]/BaF3
2. Sanger of KIF5B-RET [V804L]/BaF3
3. Anti-proliferation assay Figure 4.CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804L Cells (C1).